These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 18403799

  • 21. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 22. Crucial role of cytosolic tryparedoxin peroxidase in Leishmania donovani survival, drug response and virulence.
    Iyer JP, Kaprakkaden A, Choudhary ML, Shaha C.
    Mol Microbiol; 2008 Apr; 68(2):372-91. PubMed ID: 18312262
    [Abstract] [Full Text] [Related]

  • 23. [Effect of high temperature on promastigotes of 2 species of Leishmania].
    Savoia D, Biglino S, Cestaro A.
    G Batteriol Virol Immunol; 1991 Apr; 84(1-12):31-40. PubMed ID: 1844918
    [Abstract] [Full Text] [Related]

  • 24. Diethyldithiocarbamate, but not disulfiram, inhibits alloxan-induced dye accumulation of isolated mouse islet beta-cells.
    Norlund L, Grankvist K, Hansson HA, Norlund R.
    Med Biol; 1986 Apr; 64(1):37-41. PubMed ID: 3014237
    [Abstract] [Full Text] [Related]

  • 25. [Eco-epidemiology of visceral and cutaneous leishmaniasis in the Arab Republic of Yemen. II. A survey using intradermal reaction to leishmanin in a zone of mixed infestation with Leishmania tropica, L. donovani and L. infantum].
    Dereure J, Rageh HA, Daoud W, Rioux JA.
    Bull Soc Pathol Exot Filiales; 1989 Apr; 82(5):665-8. PubMed ID: 2633875
    [Abstract] [Full Text] [Related]

  • 26. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J, Kaur T, Kaur S.
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [Abstract] [Full Text] [Related]

  • 27. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
    Mahmoudzadeh-Niknam H, Kiaei SS, Iravani D.
    Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
    [Abstract] [Full Text] [Related]

  • 28. Cutaneous leishmaniasis serodiagnosis by immunoperoxidase assay.
    Halevy D, Sarov B, Sarov I, el-On J.
    Isr J Med Sci; 1990 Sep; 26(9):485-90. PubMed ID: 2228558
    [Abstract] [Full Text] [Related]

  • 29. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 30. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
    Sarkar K, Das PK.
    J Immunol; 1997 Jun 01; 158(11):5357-65. PubMed ID: 9164956
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [An immunologic method of producing antigens for the treatment and prevention of leishmaniasis].
    Vouldoukis I, Monjour L.
    C R Acad Sci III; 1989 Jun 01; 308(5):129-34. PubMed ID: 2493318
    [Abstract] [Full Text] [Related]

  • 33. [Differentiation among cutaneous Leishmania species upon amplification of a sequence of dipeptidyl peptidase III encoding gene].
    Kbaier-Hachemi H, Barhoumi M, Chakroun AS, Ben Fadhel M, Guizani I.
    Arch Inst Pasteur Tunis; 2008 Jun 01; 85(1-4):45-53. PubMed ID: 19469415
    [Abstract] [Full Text] [Related]

  • 34. Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs.
    Zhang WW, Chan KF, Song Z, Matlashewski G.
    Exp Parasitol; 2011 Dec 01; 129(4):337-45. PubMed ID: 21978449
    [Abstract] [Full Text] [Related]

  • 35. [Successful treatment of antimony-resistant cutaneous leishmaniasis].
    Kremsner P, Lang I, Kollaritsch H.
    Hautarzt; 1987 Dec 01; 38(12):733-5. PubMed ID: 2830206
    [Abstract] [Full Text] [Related]

  • 36. CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response.
    Gupta G, Bhattacharjee S, Bhattacharyya S, Bhattacharya P, Adhikari A, Mukherjee A, Bhattacharyya Majumdar S, Majumdar S.
    J Infect Dis; 2009 Oct 15; 200(8):1300-10. PubMed ID: 19743920
    [Abstract] [Full Text] [Related]

  • 37. [Human leishmaniases in Morocco: a nosogeographical diversity].
    Rhajaoui M.
    Pathol Biol (Paris); 2011 Aug 15; 59(4):226-9. PubMed ID: 19942371
    [Abstract] [Full Text] [Related]

  • 38. Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing Leishmania species of visceral and cutaneous forms.
    Kumar A, Boggula VR, Misra P, Sundar S, Shasany AK, Dube A.
    Acta Trop; 2010 Feb 15; 113(2):202-6. PubMed ID: 19854144
    [Abstract] [Full Text] [Related]

  • 39. Effects of disulfiram, diethyldithiocarbamate, bisethylxanthogen, and benzyl isothiocyanate on glutathione transferase activities in mouse organs.
    Benson AM, Barretto PB.
    Cancer Res; 1985 Sep 15; 45(9):4219-23. PubMed ID: 2992773
    [Abstract] [Full Text] [Related]

  • 40. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.